"The preclinical development of biopharmaceuticals or biotechnology-derived pharmaceuticals such as monoclonal antibodies, recombinant proteins, growth factors, etc. does not follow the âstandardâ rule as opposed to small molecules or new chemical entities. In addition, the biopharmaceuticals, being in essence large molecules, are susceptible to be targeted by the immune system eliciting an immunogenic reaction which can lead to adverse and even lethal and irreversible effects. This communication will discuss the cause of the onset of an immunogenic reaction and its clinical relevance when detected during the preclinical toxicity testing.
OMICS Group International is one of the leading Open Access Publishers which is publishing 700+ peer-reviewed journals with the support of 50,000+ editorial board members as editorial team and aimed to disseminate the scholarly knowledge to the scientific society. OMICS Group also organizing 3000+ International Scientific Conferences and events yearly all over the world with the support of 1000+ Scientific associations worldwide.
Citation: Maraschiello C (2014) The Relevance of Immunogenicity in Preclinical development. J Bioanal Biomed 6: 001-004."
Last date updated on August, 2020